0
0
NEW DELHI – In a significant stride for global health, researchers at the Indian Institute of Technology (IIT)-Roorkee have unveiled a promising new drug candidate designed to combat the growing threat of antibiotic resistance. This breakthrough could be a vital tool in the medical community’s fight against deadly superbugs.
The research team, spearheaded by Dr. Ranjana Pathania, has developed a molecule named Compound 3b. This compound acts as a β-lactamase inhibitor, a crucial function that prevents bacterial enzymes from dismantling powerful, life-saving antibiotics.
Compound 3b is specifically designed to work in tandem with the potent antibiotic Meropenem, restoring its effectiveness against the formidable KPC-2-producing Klebsiella pneumoniae. This particular superbug has been identified by the World Health Organization (WHO) as a top-priority threat, making the IIT-Roorkee discovery all the more critical.
Preclinical trials have yielded encouraging results. Laboratory and animal testing have demonstrated that Compound 3b successfully neutralizes the bacteria’s resistance mechanism and significantly reduces infection in the lungs. Researchers also noted that the compound is highly specific and safe for human cells, minimizing potential side effects.
This revolutionary discovery, with contributions from Mangal Singh, Perwez Bakht, and Norwegian collaborator Annette Bayer, offers a beacon of hope in a world grappling with a public health crisis. As pathogens evolve and render existing treatments ineffective, the development of new, synergistic drug candidates like Compound 3b is paramount to safeguarding future generations from infectious diseases.
Disclaimer: This news article is based on information from the referenced source and is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Reference: IIT-Roorkee unveils ‘revolutionary’ drug candidate to combat antibiotic resistance
